Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04015869 · ClinicalTrials.gov registry record · Phase 1
Effect of Allopregnanolone on Stress-induced Craving
A Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT04015869 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 10 participants.
The verdict
NCT04015869, a Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The goal of this study is to determine whether intravenous infusion of allopregnanolone (ALLO) attenuates stress-induced craving and stress-induced anxiety in a clinical laboratory setting. The secondary objective of this project is to characterize the behavioral effects of ALLO in heavy drinkers.
Interventions
- DRUG Placebos
- DRUG Allopregnanolone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-07-01 |
| Est. Completion | 2023-09-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04015869
The ClinicalTrials.gov registry entry for NCT04015869 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebos is the first listed.
NCT04015869 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04015869 about?
NCT04015869 is a clinical study titled "Effect of Allopregnanolone on Stress-induced Craving". The goal of this study is to determine whether intravenous infusion of allopregnanolone (ALLO) attenuates stress-induced craving and stress-induced anxiety in a clinical laboratory setting. The secondary objective of this project is to characterize the behavioral effects of ALLO in heavy drinkers.
What is the current status of trial NCT04015869?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2019-07-01. Estimated completion is 2023-09-01.
What interventions are being tested in trial NCT04015869?
The interventions under investigation include: Placebos (DRUG), Allopregnanolone (DRUG).
Who is sponsoring clinical trial NCT04015869?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.